biote (BTMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on May 13, 2025, with stockholders able to participate, vote, and ask questions online.
Stockholders will vote on electing two Class III directors and ratifying Deloitte & Touche LLP as the independent auditor for 2025.
Only stockholders of record as of March 24, 2025, are eligible to vote.
Proxy materials and the 2024 Annual Report are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Proposal 1: Elect Marc D. Beer and Bret Christensen as Class III directors until 2028.
Proposal 2: Ratify Deloitte & Touche LLP as independent auditor for fiscal year 2025.
Board recommends voting “For” both proposals.
Stockholder proposals for the 2026 meeting are due by December 3, 2025, for proxy inclusion.
Board of directors and corporate governance
Board consists of seven members divided into three staggered classes.
Majority of directors are independent; only the Executive Chairman and CEO are not.
Board committees: Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
Board met nine times in 2024; committee meetings were held regularly.
Board leadership structure separates CEO and Executive Chairman roles, with a lead independent director appointed.
Latest events from biote
- 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMD
Q4 202511 Mar 2026 - Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMD
Q2 20242 Feb 2026 - Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 revenue up 12.8% to $51.4M; guidance trimmed amid software and hurricane impacts.BTMD
Q3 202414 Jan 2026 - Q4 revenue up 9%, margin gains, and 2025 outlook projects further growth and profitability.BTMD
Q4 202426 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with board-backed nominees.BTMD
Proxy Filing2 Dec 2025 - Virtual meeting to elect two directors and ratify auditor, with board support for all proposals.BTMD
Proxy Filing2 Dec 2025 - Q1 net income hit $15.8M on 4.7% revenue growth; 2025 outlook and restructuring reaffirmed.BTMD
Q1 202526 Nov 2025 - Q2 2025: Dietary supplement growth, higher margins, and restructuring drove improved profitability.BTMD
Q2 202523 Nov 2025